| Attribute |
Value |
| 52 Week Change |
0.28077948 |
| Address1 |
300 Fifth Avenue |
| All Time High |
2,605.0 |
| All Time Low |
8.72 |
| Ask |
16.64 |
| Ask Size |
2 |
| Audit Risk |
8 |
| Average Analyst Rating |
1.1 - Strong Buy |
| Average Daily Volume10 Day |
408,920 |
| Average Daily Volume3 Month |
405,509 |
| Average Volume |
405,509 |
| Average Volume10Days |
408,920 |
| Bid |
10.23 |
| Bid Size |
2 |
| Board Risk |
6 |
| Book Value |
4.766 |
| City |
Waltham |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
8 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
12.91 |
| Current Ratio |
9.657 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
14.67 |
| Day Low |
12.85 |
| Debt To Equity |
0.88 |
| Display Name |
Crescent Biopharma |
| Dividend Yield |
0.0 |
| Ebitda |
-170,028,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-2.273 |
| Enterprise To Revenue |
32.518 |
| Enterprise Value |
386,405,696 |
| Eps Current Year |
-2.35333 |
| Eps Forward |
-2.63 |
| Eps Trailing Twelve Months |
-7.63 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
16.6386 |
| Fifty Day Average Change |
-3.7285995 |
| Fifty Day Average Change Percent |
-0.22409335 |
| Fifty Two Week Change Percent |
28.077948 |
| Fifty Two Week High |
27.41 |
| Fifty Two Week High Change |
-14.5 |
| Fifty Two Week High Change Percent |
-0.52900404 |
| Fifty Two Week Low |
8.72 |
| Fifty Two Week Low Change |
4.1899996 |
| Fifty Two Week Low Change Percent |
0.4805045 |
| Fifty Two Week Range |
8.72 - 27.41 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,389,364,200,000 |
| Float Shares |
27,030,582 |
| Forward Eps |
-2.63 |
| Forward P E |
-4.908745 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
69 |
| Fullday Change |
-1.5500002 |
| Fullday Change Percent |
-10.719227 |
| Fullday Price |
12.91 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,790,812,800 |
| Gross Margins |
1.0 |
| Gross Profits |
11,883,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.0026800002 |
| Held Percent Institutions |
0.82941 |
| Implied Shares Outstanding |
37,146,830 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Language |
en-US |
| Last Dividend Date |
1,673,568,000 |
| Last Dividend Value |
24.0 |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,750,032,000 |
| Last Split Factor |
1:100 |
| Long Business Summary |
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts. |
| Long Name |
Crescent Biopharma, Inc. |
| Market |
us_market |
| Market Cap |
479,565,600 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_1902132924 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
-165,124,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
527,113,517 |
| Number Of Analyst Opinions |
6 |
| Open |
14.46 |
| Operating Cashflow |
-72,679,000 |
| Operating Margins |
-14.32635 |
| Overall Risk |
10 |
| Phone |
617 460 5595 |
| Previous Close |
14.46 |
| Price Eps Current Year |
-5.4858437 |
| Price Hint |
2 |
| Price To Book |
2.7087705 |
| Price To Sales Trailing12 Months |
40.357285 |
| Profit Margins |
0.0 |
| Quick Ratio |
9.257 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
strong_buy |
| Recommendation Mean |
1.125 |
| Region |
US |
| Regular Market Change |
-1.55 |
| Regular Market Change Percent |
-10.7192 |
| Regular Market Day High |
14.67 |
| Regular Market Day Low |
12.85 |
| Regular Market Day Range |
12.85 - 14.67 |
| Regular Market Open |
14.46 |
| Regular Market Previous Close |
14.46 |
| Regular Market Price |
12.91 |
| Regular Market Time |
1,791,921,601 |
| Regular Market Volume |
197,106 |
| Revenue Per Share |
0.434 |
| Sand P52 Week Change |
0.17502642 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
10 |
| Shares Outstanding |
37,143,940 |
| Shares Percent Shares Out |
0.1286 |
| Shares Short |
4,777,172 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
3,172,374 |
| Short Name |
Crescent Biopharma, Inc. |
| Short Percent Of Float |
0.2207 |
| Short Ratio |
8.78 |
| Source Interval |
15 |
| State |
MA |
| Symbol |
CBIO |
| Target High Price |
36.0 |
| Target Low Price |
27.0 |
| Target Mean Price |
31.5 |
| Target Median Price |
31.5 |
| Total Cash |
171,592,992 |
| Total Cash Per Share |
4.009 |
| Total Debt |
1,437,000 |
| Total Revenue |
11,883,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-7.63 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
15.7842 |
| Two Hundred Day Average Change |
-2.8741999 |
| Two Hundred Day Average Change Percent |
-0.18209349 |
| Type Disp |
Equity |
| Volume |
197,106 |
| Website |
https://crescentbiopharma.com |
| Zip |
2,451 |